A double blind, crossover study of fibrinolytic enhancement treatment using stanozolol has been performed in primary Raynaud's phenomenon and in systemic sclerosis. The outcome criteria included subjective evaluation, clinical examination, physiological measurements of peripheral blood flow, and fibrinolytic measurements. Nineteen patients entered and 11 completed the study of primary Raynaud's phenomenon. There was nonsignificant evidence of improvement in peripheral blood flow. Twenty four patients entered and 17 completed the study ofsystemic sclerosis. There was marked objective but not subjective evidence of improvement in the peripheral microcirculation during the stanozolol treatment period. There was also a nonsignificant improvement in dermal sclerosis. There were improvements in fibrinolytic activity during the stanozolol treatment period. There was no alteration in fibrinolytic reserve as measured by 1-desamino-8-D-arginine vasopressin stimulation, however. Although adverse events were common in both treatment periods, withdrawals predominantly occurred during the period of treatment with stanozolol and were principally due to anabolic problems. There does not seem to be any indication for the use of stanozolol in primary Raynaud's phenomenon. Fibrinolytic enhancement with stanozolol does appear useful in treating the microvascular features of systemic sclerosis.
Raynaud's phenomenon is a syndrome in which exposure to cold and often other stimuli produces transient digital ischaemia with a biphasic or triphasic colour change commonly associated with numbness and paraesthesiae. In primary Raynaud's phenomenon no underlying cause can be found, whereas in secondary Raynaud's phenomenon, connective tissue diseases and, in particular, systemic sclerosis are important causes. Systemic sclerosis is characterised by progressive vascular obstruction, excessive proliferation of connective tissue elements, and, especially, collagen and ischaemic atrophy of the tissues. Patients commonly have severe Raynaud's phenomenon, often complicated by digital pitting and ulceration. The characteristic vascular disease includes arteriolar intimal proliferation with fibrin deposition associated with endothelial damage and platelet aggregation and adherence. These changes lead to progressive vascular obstruction. In addition, there is hyperfibrinogenaemia with hyperviscosity of the blood,' particularly at low temperatures and at low shear rates2 as occurs in peripheral vessels in the hands with defective fibrinolytic activity.3 For this reason stimulation of the fibrinolytic system and correction of this fibrinolytic defect may be of therapeutic value in correcting the vascular problems by improving vascular patency and reducing plasma viscosity. 4 We therefore conducted a double blind, controlled trial of stimulating the fibrinolytic system with stanozolol, which is an anabolic steroid with low virilising potential and is known to enhance and normalise impaired fibrinolytic activity.
Patients and methods

PATIENTS
Nineteen patients with primary Raynaud's phenomenon (17 women, two men; mean age 43-3 (SE 3-3) years; mean duration of disease 109X3 (SE 27 8) months) and 24 patients with systemic sclerosis (22 women, two men; mean age 50 5 (2 8) years; mean duration of disease 206O0 (32 7) months) entered the study. Patients were not taking drugs which might influence fibrinolytic activity, and had no evidence of cardiac, hepatic, renal or other disease known to influence fibrinolysis or which might contraindicate the use of stanozolol. Women patients, additionally, were not pregnant, had no risk of pregnancy, or were using effective contraceptive methods, excluding the pill. There were seven current smokers in the group with primary Raynaud's phenomenon and seven in the group with systemic sclerosis. All gave written informed consent and the study was performed with the approval of the Salford ethical committee.
Patients with primary Raynaud's phenomenon had bilateral symmetrical Raynaud's phenomenon, with at least two of the three colour changes in response to cold, with no evidence of mechanical or drug induced causes of Raynaud's phenomenon, and no clinical or laboratory evidence of connective tissue disorders, including negative tests for antinuclear factor, extractable nuclear antigen, and anticentromere antibody.
Patients with systemic sclerosis satisfied the American Rheumatism Association criteria5 for defmite systemic sclerosis and also had Raynaud's phenomenon. TREATMENT Treatment was with either stanozolol 5 mg orally twice a day or matching placebo tablets twice a day. Patients were randomly allocated to receive six months treatment with stanozolol or placebo given in a double blind fashion and then crossed over to the alternate regimen for a further period of six months.
ASSESSMENTS
Assessments were performed one week before entry, on entry to the study, and at four, 12, and 24 weeks of the first treatment period, and again at four, 12, and 24 weeks of the second treatment period.
Adverse events were assessed by a standard questionnaire covering all possible problems before entry to the trial and at each assessment. A blood count, renal and liver function tests, and urine examination were undertaken at each assessment.
On entry patients underwent detailed assessments of the severity and duration of disease. To assess progress sequential measurements of clinical and physiological variables and fibrinolytic changes were made.
Clinical variables A subjective assessment was obtained by noting the frequency and duration of Raynaud's phenomenon using diary cards.
For patients with systemic sclerosis a measurement of skin disease was made with a modified Rodnan scleroderma skin score, grip strengths in both hands, the ability to make a fist measured by the sum of the distances between the finger tips and the transverse palm crease, the intervermilion distance on opening the mouth, and the degrees of fixed flexion of the elbows. The data were analysed to determine whether there were any carry over effects for the incidence and duration of Raynaud's attacks and the reporting of adverse events between the stanozolol and placebo periods of treatment. 6 No significant effects were detected. The subsequent analyses combined the data from both treatment periods.
Physiological variables
The changes occurring within each treatment period and the differences between the effects of the stanozolol and placebo treatment periods were tested with Student's t test.
Results
SUBJECTS STUDIED AND ADVERSE EVENTS
Of the 21 patients with primary Raynaud's phenomenon, 11 completed the study receiving both stanozolol and placebo for a period of six months each. Two patients were excluded (one through lack of interest, one was too young). Seven patients withdrew during the stanozolol treatment period and one while being treated with placebo. Despite the precautions listed in the entry criteria two had become pregnant, one while receiving stanozolol and the other during the placebo period. The trial drug was stopped at 12 and seven weeks ofpregnancy respectively; spontaneous abortions occurred a further five and three weeks later. Of the 24 patients with systemic sclerosis, 17 completed the study and seven withdrew, six while receiving stanozolol and one during the placebo period.
An attempt was made to analyse the effects of the weather on the study. This proved extremely difficult. Study of the data, however, showed that the assessments were similarly distributed in the warmer and cooler halves of the year for both stanozolol and placebo treatment periods. (p=0 27) of attacks. The differences between the placebo and stanozolol periods were not statistically significant.
Physiological changes There were no significant changes in the Doppler index during either 24 week treatment period.
After 24 weeks' treatment with stanozolol there were increases in the mean finger pulp skin temperature (p=0-18) and in the nailbed skin temperature (p=O 16). After 24 weeks' treatment with placebo there was a reduction in mean finger pulp finger temperature (p=007) and in the mean nailbed skin temperature (p=0 05). The changes of the mean finger pulp and nailbed skin temperatures were not significantly different between the two treatment periods (p=0 10 and 0 08) after 24 weeks.
Fibrinolytic changes
After 24 weeks' stanozolol treatment there were significant reductions in the ELT both in the basal measurements (p=0 007) and after DDAVP stimulation (p=002). There were non-significant increases after 24 weeks' treatment with placebo. There were significant differences between the two treatment periods in the basal (p=0 05) and post-DDAVP (p=002) measurements of ELT (table 2) .
After 24 weeks' stanozolol treatment there were significant increases in the fasting (p=00009) and post-DDAVP (p=005) measurements of the FPLA. With placebo there was a significant reduction in the fasting FPLA (p=002) and a non-significant reduction (p=0-17) after DDAVP. The differences in fasting FPLA between the two treatment periods were significantly different (p=00009) (table 2).
There was a significant reduction in plasma fibrinogen (p=0 04) after 24 weeks of treatment with stanozolol and a non-significant increase after 24 weeks with placebo. The differences between treatments were not significantly different (p=0 06) (table 3) .
There was a significant increase in plasminogen (p=0 003) with stanozolol treatment but no significant change with placebo. The differences between the two treatments were significantly different (p=0 03) (table 3) .
No significant changes were found in the a2 antiplasmin or a2 macroglobulin concentrations.
SYSTEMIC SCLEROSIS STUDY
Clinical changes There were reductions in the mean frequency of Raynaud's attacks during both stanozolol (p=045) and placebo (p=0 44) treatment. These changes did not reach statistical siglnificance, and there were no significant differences between the two treatment periods (p=094). The duration of individual attacks fell after 24 weeks' treatment with stanozolol (p=Ot38) and increased after placebo (p=063). These changes were not significant and there were no Jayson, Holland, Keegan, Illinguorth, Taylor significant differences between the two treatment periods (p=044).
The scleroderma skin score remained unchanged during placebo treatment and fell with stanozolol, but the changes were not significant (fig 1) .
Mean grip strength (fig 2) increased after treatment with stanozolol (p=0 14) and decreased with placebo (p=0 15). These changes and the differences between them were not significant (p=007).
Physiological changes
There was a significant increase in the ultrasonic Doppler index (fig 3) after 24 weeks' treatment with stanozolol (p=0 006) and a significant decrease with placebo (p=0 02). The difference between the two treatment periods was significant (p=0007).
During stanozolol treatment there were significant increases in finger pulp (p=0001) and nailbed (p=0001) temperatures, whereas after placebo there was a non-significant decrease in finger pulp (p=0-08) and a significant decrease in nailbed (p=004) temperatures. The differences between stanozolol and placebo periods Stanozolol is an anabolic steroid with relatively little androgenic activity. It has been shown to enhance impaired fibrinolytic activity.9 In lipodermatoscierosis there is chronic induration and fibrosis of the skin and subcutaneous tissues of the leg after deep venous thrombosis. Fibrin is deposited in the tissues and there is a fibrinolytic defect in the blood. Fibrinolytic enhancement with stanozolol is effective in correcting the defect, reducing the fibrin in the tissues and reducing the area of liposclerosis.'0 Clinical improvements by similar mechanisms are suggested in rheumatoid arthritis" and in cutaneous vasculitis. 12 A previous study of systemic sclerosis and Raynaud's phenomenon suggested stanozolol is of value.4 This was an uncontrolled study, however in which patients received stanozolol for two periods of three months with an intervening period of three months without drug treatment. Raynaud's phenomenon and systemic sclerosis are extremely difficult to assess and placebo controlled studies are essential to evaluate any form of treatment. Moreover, although the authors state the trial was in patients with both idiopathic and scleroderma associated Raynaud's phenomenon, they did not define the criteria for either group. All these 20 patients in the trial had severe bilateral disease with trophic changes and symptoms such as pain and recurrent infection in the finger tips. From review of the paper it seems likely that they all had systemic connective tissue disease. We have conducted, therefore, further and more detailed studies to determine the clinical, physiological, and biochemical effects of stanozolol in patients with primary Raynaud's phenomenon and systemic sclerosis.
Assessment of Raynaud's phenomenon is notoriously difficult. In particular, in long term studies subjective assessments of frequency and severity of Raynaud's attacks are complicated by change in season and it can be very difficult to determine the values of any form of treatment without objective measures of peripheral blood flow after stabilisation at controlled temperatures. Patients have more and longer attacks in the winter than in the summer and it is possible that winter weather plus an effective agent equates with summer weather plus placebo so that a real effect might be missed. For these reasons we attach much greater value to the objective measurements than to the subjective recordings of frequency and duration of Raynaud's attacks.
In patients with primary Raynaud's phenomenon there were some small non-significant trends towards improvement in the peripheral microcirculation during the stanozolol treatment periods compared with the control treatment periods. It remains possible that some of these patients with primary Raynaud's phenomenon were in the early stages of connective tissue disease but without any clinical features. Benefit in these subjects might account for the minor improvements that were seen. In view of the side effects there is no indication for stanozolol in primary Raynaud's phenomenon.
In the patients with systemic sclerosis the duration of Raynaud's attacks fell during stanozolol treatment and increased with placebo, though these differences were not significant.
The objective measures of peripheral blood flow, however, showed significant improvements during stanozolol treatment compared with placebo. These differences were marked in terms of digital patency measured by the ultrasonic Doppler index and skin temperatures both of the finger pulps and nail beds. These results indicate a marked improvement in the microcirculation during the period of stanozolol treatment.
Anecdotal evidence suggests that fibrinolytic enhancement is most effective if given early in the disease. Once vessels are totally occluded, and perhaps fibrin deposits are stabilised and the patient is showing major evidence of peripheral ischaemia possibly with digital gangrene, only limited improvement, if any, may be expected during treatment with stanozolol. A further trial of fibrinolytic enhancement specifically limited to early systemic sclerosis is indicated.
We also found a non-significant improvement in the scleroderma skin score, which is an index of the degree of skin affected by fibrotic change. The number of patients in this study was small. It remains possible that a larger study of longer duration might show significant improvement of skin involvement during treatment with stanozolol.
The grip strength increased during stanozolol treatment and decreased during the control periods. If this is a real change it may reflect the control of the underlying disease. Differences in grip strength may be due to the anabolic effects of stanozolol on muscle strength, however.
Defective fibrinolytic activity is well recognised in systemic sclerosis but not in carefully defined primary Raynaud's phenomenon.3 In this study we found a prolonged ELT and reduced FPLA in the patients with systemic sclerosis compared with those with primary Raynaud's phenomenon. Stanozolol is known to stimulate fibrinolytic activity,9 and in the current studies we found that the treatment period was associated with a fall in the ELT, an increase in the FPLA, and a reduction in plasma fibrinogen concentrations. Fibrinolytic activity is determined by the concentrations of tissue plasminogen activator, which is derived from the vascular endothelium. ' There does not seem to be any indication for the use of stanozolol in primary Raynaud's phenomenon. In systemic sclerosis there was a significant and marked improvement in the peripheral microcirculation by objective but not subjective measures, and a non-significant improvement in the scleroderma skin score. Adverse effects again were common. Stanozolol does seem to be useful in treating the microvascular features of systemic sclerosis.
